IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) has earned a consensus recommendation of “Reduce” from the ten analysts ...

In yet another early year blow for the Bay Area’s biotech workforce, IGM Biosciences is laying off almost three-fourths of its staff after a crucial clinical study delivered poor results.

IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 ...

Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory ...

NASDAQ IGMS opened at $2.09 on Friday. IGM Biosciences has a 1-year low of $1.87 and a 1-year high of $22.50. The company has a market capitalization of $124.28 million, a price-to-earnings ratio ...